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Abstract
Introduction: Alterations in haemoglobin levels are frequent in stroke patients. The prognostic meaning of anaemia
and polyglobulia on outcomes in patients treated with intravenous thrombolysis is ambiguous.
Patients and methods: In this prospective multicentre, intravenous thrombolysis register-based study, we compared
haemoglobin levels on hospital admission with three-month poor outcome (modified Rankin Scale 3–6), mortality and
symptomatic intracranial haemorrhage (European Cooperative Acute Stroke Study II-criteria (ECASS-II-criteria)).
Haemoglobin level was used as continuous and categorical variable distinguishing anaemia (female: <12 g/dl; male:
<13 g/dl) and polyglobulia (female: >15.5 g/dl; male: >17 g/dl). Anaemia was subdivided into mild and moderate/severe
(female/male: <11 g/dl). Normal haemoglobin level (female: 12.0–15.5 g/dl, male: 13.0–17.0 g/dl) served as reference
group. Unadjusted and adjusted odds ratios with 95% confidence intervals were calculated with logistic regression models.
Results: Among 6866 intravenous thrombolysis-treated stroke patients, 5448 (79.3%) had normal haemoglobin level,
1232 (17.9%) anaemia – of those 903 (13.2%) had mild and 329 (4.8%) moderate/severe anaemia – and 186 (2.7%)
polyglobulia. Anaemia was associated with poor outcome (ORadjusted 1.25 (1.05–1.48)) and mortality (ORadjusted 1.58
(1.27–1.95)). In anaemia subgroups, both mild and moderate/severe anaemia independently predicted poor outcome
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(ORadjusted 1.29 (1.07–1.55) and 1.48 (1.09–2.02)) and mortality (ORadjusted 1.45 (1.15–1.84) and ORadjusted 2.00 (1.46–
2.75)). Each haemoglobin level decrease by 1 g/dl independently increased the risk of poor outcome (ORadjusted 1.07
(1.02–1.11)) and mortality (ORadjusted 1.08 (1.02–1.15)). Anaemia was not associated with occurrence of symptomatic
intracranial haemorrhage. Polyglobulia did not change any outcome.
Discussion: The more severe the anaemia, the higher the probability of poor outcome and death. Severe anaemia might
be a target for interventions in hyperacute stroke.
Conclusion: Anaemia on admission, but not polyglobulia, is a strong and independent predictor of poor outcome and
mortality in intravenous thrombolysis-treated stroke patients.
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Introduction
Alterations in haemoglobin levels (HLs) on admission
are frequently (anaemia up to 25%) observed in acute
stroke patients.1,2 In general stroke populations, anae-
mia was associated with poorer outcomes1,3–5 except for
one study.6 Only one smaller study (n¼ 217) has inves-
tigated the effect of anaemia on outcomes in stroke
patients treated with intravenous thrombolysis (IVT).
In this study, the development of anaemia or worsening
of anaemia in the first days after admission was associ-
ated with poor functional outcome and mortality but
not the presence of anaemia on admission.7 A second
study, including both IVT (n¼ 466) and endovascular
treated patients (n¼ 712), found anaemia on admission
being an independent predictor of poor functional out-
come and mortality.8 From a pathophysiological point
of view, low HL at stroke onset is likely to impair out-
comes due to a mismatch between increased metabolic
requirements of the penumbral brain tissue and lowered
oxygen transport capacity and reduced blood perfusion.
Furthermore, HL might also affect outcomes via alter-
ations in cerebrovascular autoregulation, blood coagu-
lation and inflammatory mediators.1,9–12
On the other side of the spectrum, the presence of
polyglobulia in the general stroke population was asso-
ciated with mortality in one1 but not in another study.4
Therefore, the prognostic meaning of anaemia and pol-
yglobulia on outcomes in patients treated with IVT
remains unclear.
The aim of this study was to investigate the effect of
baseline HL on functional outcome, mortality and bleed-
ing risk in a large cohort of IVT-treated stroke patients.
Methods
For this cohort study, we used prospectively collected
data from the ThRombolysis in Ischemic Stroke
Patients (TRISP) registry which has been previously
described.13 Ten TRISP centres participated in this
study (eTable 1). A complete list of all TRISP centres
is presented in the online supplement (eAppendix 1).
Data collection was done locally in each stroke centre
using a standardised form with predefined parame-
ters.14,15 Data of the local registries were pooled and
analysed at the stroke centre Basel. Parameters of inter-
est for the present study were age, sex, National
Institutes of Health Stroke Scale (NIHSS) score,16
blood pressure prior to IVT treatment, onset-to-
treatment time, estimated glomerular filtration rate
using the CKD-EPI formular,17 glucose levels and
HL in blood serum on admission, vascular risk factors
according to predefined criteria13,18 and prior treat-
ment with antithrombotic agents (antiplatelet agents
or anticoagulants). Outcome parameters were mortali-
ty and the modified Rankin Scale (mRS) score at three
months assessed either by outpatient visits or telephone
calls with patients and/or relatives. Poor functional
outcome was defined as a mRS score of 3–6. As
safety outcome we defined the occurrence of symptom-
atic intracranial haemorrhage (sICH) using the
ECASS-II-criteria.19 Intracranial haemorrhage was
monitored by follow-up CT or MRI – in most cases
performed at 24 h after start of IVT and immediately in
case of neurological detorientation – as described in
prior research.15,20
Included data were collected up to 30 January 2014
(eTable 1). All patients with missing data on (i) HL, (ii)
three-month outcome and (iii) sICH-data were
excluded.
Statistical analyses
Statistical analyses were performed with SPSS
Statistics version 25 (IBM) and STATA version 14.1
(StataCorp LP).
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We investigated associations between HL and out-
come measures using HL as a (i) continuous variable
and as a (ii) categorical variable distinguishing anaemia
(female: <12 g/dl; male: <13 g/dl) and polyglobulia
(female: >15.5 g/dl; male: >17 g/dl) defined by the cri-
teria of the World Health Organisation (WHO).21
Normal HL (female: 12–15.5 g/dl; male: 13–17 g/dl)
served as reference group. According to the grading
system of the WHO, anaemia was further subdivided
into mild (female: 11–11.9 g/dl; male: 11–12.9 g/dl) and
moderate/severe (female/male: <11 g/dl).22
Continuous data were summarised as median and
interquartile range. We used Chi2-test and Fisher’s
exact test for categorical variables where appropriate
and the Mann–Whitney U-test for continuous varia-
bles. The association between HL and each outcome
was estimated by calculating odds ratios (OR) with
95% confidence intervals (95% CI), using binary logis-
tic regression models. All variables with p< 0.05 were
included in the multivariable analyses using stepwise
regression with backward elimination. To avoid over-
fitting, the maximum number of potential confounders
in the final model was restricted to one-tenth of the
number of outcome events. Predictive margins of the
adjusted logistic regression models are displayed in
Figure 1.
Receiver operating characteristic (ROC) and area
under the curve (AUC) were calculated to show
the accuracy of HL to predict poor outcome and
mortality.
The study was approved by the ethics committee in
Basel, Switzerland. The requirement for additional
local ethical approval differed between participating
centres and was obtained if required. Anonymised
data will be shared by request from any qualified
investigator.
Results
Data were eligible for analysis in 6866 (92.8%) of the
7395 IVT-treated patients. Reasons for excluding
patients were missing data on HL (n¼ 213; 2.9%),
three-month outcome (n¼ 257; 3.5%) or sICH
(n¼ 59; 0.8%).
Among study patients, 5448 (79.4%) had normal
HL, 1232 (17.9%) anaemia and 186 (2.7%)
polyglobulia.
Anaemia versus normal HL
Baseline characteristics are presented in Table 1.
Patients with anaemia were older, had more severe
strokes, lower median systolic blood pressure, lower
eGFR at stroke onset, more frequently on antithrom-
botics (antiplatelets and/or anticoagulation) and were
more likely to have a history of atrial fibrillation, cor-
onary artery disease, diabetes mellitus, hypertension
and prior stroke compared to patients with normal
HL. Patients with anaemia more often had poor func-
tional outcome (55.5% versus 39.5%) and died more
often (22.4% versus 11.3%) during the three-month
follow-up, while the proportion of patients with symp-
tomatic ICH did not differ significantly (4.5% versus
4.3%). Data of recurrent strokes within three months
after stroke onset were available in a subgroup of
patients only (n¼ 2518, centres of Amsterdam, Basel,
Belgrade, Bern, Brescia and Modena). Frequency of
recurrent stroke did not differ significantly between
patients with anaemia and normal HL (3.3% versus
3.4%) as well as between polyglobulia and normal
HL (3.3% versus 4.9%). (Table 1)
Anaemia was associated with poor functional out-
come (ORunadjusted 1.91, 95% CI 1.69–2.17 and
ORadjusted 1.25, 95% CI 1.05–1.48) and mortality
Figure 1. Predictive margins with 95% CI of the adjusted logistic regression models showing the association of haemoglobin levels
and outcomes in IVT-treated stroke patients: (a) adjusted for age, stroke severity (NIHSS), glucose, eGFR, RF diabetes and (b) adjusted
for age, stroke severity (NIHSS), RF diabetes.
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(ORunadjusted 2.28, 95% CI 1.94–2.67 and ORadjusted
1.58, 95% CI 1.27–1.95) but not with sICH
(ORunadjusted 1.04, 95% CI 0.82–1.33 and ORadjusted
0.94, 95% CI 0.69–1.30). The lack of association
between HL and sICH remained irrespective of type
of antithrombotic treatment (antiplatelet and/or anti-
coagulation) (Tables 2 and 3).
Mild and moderate to severe anaemia versus
normal HL
Of 1232 patients with anaemia, 903 (73.3%) had mild
anaemia and 329 (26.7%) moderate/severe anaemia.
Baseline characteristics of both anaemia subgroups
are presented in Table 1. Patients with mild and mod-
erate/severe anaemia had more frequently poor func-
tional outcome (52.9 and 62.6% versus 39.5% in
patients with normal HL) and mortality (20.7 and
27.1% versus 11.3% in normal HL). Frequency of
sICH did not differ significantly between patients
with mild anaemia (4.8%), moderate/severe anaemia
(4.0%) and normal HL (4.3%) (Table 1). Mild anaemia
was associated with poor functional outcome
(ORunadjusted 1.72, 95% CI 1.50–1.99) and mortality
(ORunadjusted 2.06, 95% CI 1.72–2.47). These associa-
tions remained significant after adjustment for poten-
tial confounders (poor functional outcome: OR 1.29,
95% CI 1.07–1.55 and mortality: OR 1.45, 95% CI
1.15–1.84). Similarly, moderate/severe anaemia was
associated with poor functional outcome (ORunadjusted
2.57, 95% CI 2.04–3.23; ORadjusted 1.48, 95% CI 1.09–
2.02) and mortality (ORunadjusted 2.93, 95% CI 2.26–
3.78; ORadjusted 2.0, 95% CI 1.46–2.75). Neither mild
nor moderate/severe anaemia was associated with the
occurrence of sICH (Tables 2 and 3).
Polyglobulia versus normal HL
Compared to normal HL, polyglobulia (n¼ 186;
2.71%) did not significantly change the odds for any
outcome (poor functional outcome ORunadjusted 0.86,
95% CI 0.64–1.17; mortality ORunadjusted 0.9, 95% CI
Table 2. Univariate analysis of clinical characteristics (odds ratio with 95% confidence interval) in IVT patients.
Putative predicting variables sICH Poor outcomea Mortality
Age (each year) 1.01 (1.01–1.03) p< 0.001 1.05 (1.04–1.05) p< 0.001 1.07 (1.06–1.08) p< 0.001
Sex 1.07 (0.88–1.23) p¼0.516 1.51 (1.37–1.67) p< 0.001 1.34 (1.16–1.54) p< 0.001
NIHSS (each point) 1.07 (1.06–1.09) p< 0.001 1.18 (1.17–1.20) p< 0.001 1.16 (1.14–1.17) p< 0.001
Systolic blood pressure (each mmHg) 1.00 (1.00–1.01) p¼ 0.032 1.00 (1.00–1.01) p¼ 0.011 1.00 (1.00–1.01) p¼ 0.032
Stroke-to-needle (each minute) 1.00 (0.99–1.00) p¼ 0.235 1.00 (1.00–1.00) p¼ 0.136 1.00 (0.99–1.00) p¼ 0.389
Decreasing eGFR (by 10 ml/min) 1.00 (1.00–1.01) p< 0.001 1.02 (1.02–1.02) p< 0.001 1.03 (1.02–1.03) p< 0.001
Glucose (each mmol/l) 1.03 (1.01–1.06) p¼ 0.004 1.09 (1.07–1.11) p< 0.001 1.09 (1.06–1.11) p< 0.001
Prior antithrombotics 1.22 (0.96–1.55) p¼ 0.113 1.47 (1.33–1.63) p< 0.001 1.99 (1.73–2.29) p< 0.001
Antiplatelets 1.20 (0.93–1.55) p¼ 0.163 1.34 (1.20–1.40) p< 0.001 1.71 (1.47–1.99) p< 0.001
Anticoagulation with or
without antiplatelets
0.93 (0.50–1.72) p¼ 0.817 1.88 (1.47–2.41) p< 0.001 2.12 (1.59–2.83) p< 0.001
Atrial fibrillation 1.45 (1.19–1.78) p< 0.001 1.93 (1.74–2.16) p< 0.001 2.01 (1.74–2.33) p< 0.001
Hypertension 1.19 (0.96–1.46) p¼ 0.107 1.50 (1.35–1.66) p< 0.001 1.61 (1.37–1.89) p< 0.001
Smoking 0.67 (0.51–0.90) p¼ 0.007 0.70 (0.62–0.81) p< 0.001 0.50 (0.40–0.63) p< 0.001
Hypercholesterolemia 1.10 (0.91–1.33) p¼ 0.321 0.86 (0.78–0.95) p¼ 0.003 0.85 (0.74–0.98) p¼ 0.025
Diabetes mellitus 1.33 (1.06–1.68) p¼ 0.014 1.67 (1.47–1.87) p< 0.001 1.67 (1.41–1.97) p< 0.001
Coronary artery disease 1.38 (1.10–1.72) p¼ 0.005 1.44 (1.27–1.62) p< 0.001 1.95 (1.67–2.28) p< 0.001
Prior stroke 1.17 (0.90–1.51) p¼ 0.237 1.35 (1.18–1.54) p< 0.001 1.48 (1.24–1.78) p< 0.001
Anaemiab versus normal HL 1.04 (0.82–1.33) p¼ 0.744 1.91 (1.69–2.17) p< 0.001 2.28 (1.94–2.67) p< 0.001
Mild anaemiac versus normal HL 1.11 (0.80–1.55) p¼ 0.542 1.72 (1.50–1.99) p< 0.001 2.06 (1.72–2.47) p< 0.001
Moderate/severe anaemiad
versus normal HL
0.91 (0.52–1.61) p¼ 0.753 2.57 (2.04–3.23) p< 0.001 2.93 (2.26–3.78) p< 0.001
Polyglobuliae versus normal HL 0.79 (0.41–1.50) p¼ 0.469 0.86 (0.64–1.17) p¼ 0.343 0.90 (0.55–1.45) p¼ 0.660
Decreasing HL (by 1 g/dl) 1.04 (0.98–1.10) p¼ 0.160 1.22 (1.19–1.26) p< 0.001 1.24 (1.19–1.29) p< 0.001
eGFR: estimated glomerular filtration rate; HL: haemoglobin level; IVT: intravenous thrombolysis; NIHSS: National Institutes of Health Stroke Scale;
sICH: symptomatic intracerebral haemorrhage (ECASS II definition).
aPoor outcome: modified Rankin Scale 3–6.
bAnaemia¼ haemoglobin female: < 12 g/dl; male: < 13 g/dl.
cMild anaemia¼ haemoglobin female: 11–11.9 g/dl; male: 11–12.9 g/dl.
dModerate/severe anaemia¼ haemoglobin < 11 g/dl.
ePolyglobulia¼ haemoglobin female: >15.5 g/dl; male: >17 g/dl.
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0.55–1.45; sICH ORunadjusted 0.79, 95% CI 0.41–1.50)
(Tables 1 to 3).
HL as a continuous variable
The adjusted logistic regression model showed an
increasing probability of poor outcome and mortality
with decreasing HL. A decrease in HL by 1 g/dl was
associated with an OR of 1.07 (95% CI 1.02–1.11) for
poor outcome and with an OR of 1.08 (95% CI 1.02–
1.15) for mortality. HLs were not significantly associ-
ated with sICH (Figure 1 and Table 3).
The ability of HL to predict poor functional out-
come or mortality was low (AUC of ROC curve for
poor functional outcome: 0.59 (95% CI 0.58–0.61,
p< 0.001); for mortality: 0.60 (95% CI 0.58–0.62,
p< 0.001) (eFigure 1).
Discussion
This study showed the following key results for the
association between HL and outcomes in acute ischae-
mic stroke patients treated with IVT: (i) 17.9% of
IVT-treated stroke patients had anaemia on admission.
(ii) Anaemia was an independent predictor for poor
functional outcome and mortality in IVT-treated
stroke patients, but not for symptomatic ICH. (iii)
The more severe the anaemia the higher the probability
of poor functional outcome and mortality. (iv)
Polyglobulia was not associated with any outcome.
In our study population, 17.9% of patients had
anaemia (according to the WHO criteria) on admission
and before IVT administration. Presence of anaemia
independently increased the probability of poor func-
tional outcome after three months of follow-up by 25%
and the probability of mortality by 60%. Previously,
only one smaller observational study (n¼ 217) has
investigated the impact of HL on outcomes in IVT-
treated stroke patients.7 Although the proportion of
patients with anaemia on admission was higher in
patients with poor functional outcome (20.4%) com-
pared to patients with favourable functional outcome
(10.5%; p¼ 0.04), HLs on admission were not indepen-
dently associated with poor functional outcome
(p¼ 0.20) or mortality (p¼ 0.45). However, the
Table 3. Multivariate analysis of outcomes (odds adjusted for variables with p< 0.05 in the univariate analysis). Odds ratio (95%
confidence interval), p-value.
Outcome measures
Putative predicting variables sICH Poor outcomea Mortality
Anaemia versus normal HL 0.94 (0.69–1.30)b p¼ 0.718 1.25 (1.05–1.48)c p¼ 0.012 1.58 (1.27–1.95)d p< 0.001
Mild anaemia versus normal HL 1.03 (0.73–1.46)e p¼ 0.865 1.29 (1.07–1.55)f p¼ 0.009 1.45 (1.15–1.84)g p¼ 0.002
Moderate/severe anaemia
versus normal Hb
0.72 (0.40–1.30)h p¼ 0.277 1.48 (1.09–2.02)i p¼ 0.013 2.00 (1.46–2.75)j p<0.001
Decreasing HL (by 1 g/dl) 1.02 (0.94–1.11)k p¼ 0.652 1.07 (1.02–1.11)l p¼ 0.004 1.08 (1.02–1.15)m p¼ 0.010
HL: haemoglobin level; sICH: symptomatic intracerebral haemorrhage (ECASS II definition).
aPoor outcome: modified Rankin Scale 3–6.
bNIHSS on admission, age, CKD-EPI, pre-antithrombotic any, anaemia.
cNIHSS on admission, age, glucose on admission, CKD-EPI, RF diabetes, RF hypertension, RF coronary artery disease, gender, smoking, pre-antith-
rombotic any, RF atrial fibrillation, RF hypercholesterolemia, RR systole on admission, RF prior ischaemic stroke, anaemia.
dNIHSS on admission, age, glucose on admission, CKD-EPI, RF diabetes, RF hypertension, RF coronary artery disease, gender, smoking, pre-antith-
rombotic any, RF atrial fibrillation, RF hypercholesterolemia, RR systole on admission, RF prior ischaemic stroke, anaemia.
eNIHSS on admission, age, CKD-EPI, pre-antithrombotic any, mild anaemia.
fNIHSS on admission, age, stroke-to-needle-time, glucose on admission, CKD-EPI, RF diabetes, RF hypertension, RF coronary artery disease, gender,
pre-antithrombotic any, RF atrial fibrillation, RF hypercholesterolemia, RR systole on admission, RF prior ischaemic stroke, mild anaemia.
gNIHSS on admission, age, stroke-to-needle-time, glucose on admission, CKD-EPI, RF diabetes, RF hypertension, RF coronary artery disease, gender,
pre-antithrombotic any, RF atrial fibrillation, RF hypercholesterolemia, RR systole on admission, RF prior ischaemic stroke, mild anaemia.
hNIHSS on admission, severe anaemia.
iNIHSS on admission, age, stroke-to-needle-time, glucose on admission, CKD-EPI, RF diabetes, RF hypertension, RF coronary artery disease, gender,
pre-antithrombotic any, RF atrial fibrillation, RF hypercholesterolemia, RR systole on admission, RF prior ischaemic stroke, current smoking, severe
anaemia.
jNIHSS on admission, age, gender, glucose on admission, CKD-EPI, prior stroke, RR on admission, serve anaemia.
kNIHSS on admission, age, glucose on admission, CKD-EPI, RF diabetes, RF coronary artery disease, smoking, pre-antithrombotic any, RF atrial
fibrillation, RR systole on admission, decreasing HL in g/dl.
lNIHSS on admission, age, glucose on admission, CKD-EPI, RF diabetes, RF hypertension, RF coronary artery disease, gender, smoking, pre-antith-
rombotic any, RF atrial fibrillation, RF hypercholesterolemia, RR systole on admission, RF prior ischaemic stroke, decreasing HL in g/dl.
mNIHSS on admission, age, glucose on admission, CKD-EPI, RF diabetes, RF hypertension, RF coronary artery disease, gender, smoking, pre-
antithrombotic any, RF atrial fibrillation, RF hypercholesterolemia, RR systole on admission, RF prior ischaemic stroke, decreasing HL in g/dl.
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number of patients with anaemia was small (n¼ 33),
though the proportion (i.e. 15%) resembled that of
the present study (i.e. 17.9%). Interestingly, after inclu-
sion of patients who had developed anaemia during the
first five days of hospitalisation into analysis (n¼ 86),
anaemia was independently associated with poor func-
tional outcome (OR 2.61, 95% CI 1.33–5.11) but still
not with mortality (p¼ 0.13). A recent study, including
IVT and endovascular treated patients, found that
anaemia at hospital admission and any decrease of
haemoglobin were associated with poor functional out-
come and higher mortality.8
The large sample size in the present study allowed a
subgroup analysis of patients with mild and moderate/
severe anaemia. Data on anaemia subgroups are scarce.
One retrospective study after mechanical thrombec-
tomy23 (n¼ 90) reported an association between
severe anaemic patients (Hb<10 g/dl) and poor func-
tional outcome but not for patients with mild anaemia.
In our study, both mild and moderate/severe anaemic
patients were independently associated with poor func-
tional outcome and mortality but the odds were higher
in the moderate/severe group. In line, the probability
for poor functional outcome and mortality increased
with decreasing HL. Every decrease in HL by 1 g/dl
increased the probability of poor outcome by 7% and
the probability of mortality by 8%.
Several underlying pathophysiological mechanisms
could explain the association between anaemia and
an increased probability of poor functional outcome
and mortality. Arterial oxygen content depends on
HL and arterial oxygen saturation. The oxygen content
and cerebral blood flow determine oxygen delivery to
the brain. Consequently, decreasing HL lowers the
arterial oxygen content and possibly leads to changes
in blood flow resulting in an impaired tissue oxygen
supply. Therefore, hypoxia in penumbral lesions may
be increased leading to more extensive ischaemic
areas.24,25
Furthermore, anaemia could compromise the cere-
bral autoregulation which maintains cerebral blood
flow and oxygen carrying capacity through collaterals
to penumbral lesions.26,27 Healthy patients with anae-
mia might tolerate hypoxia with an HL of approxi-
mately down to 8 g/dl.25 However, in anaemic stroke
patients who likely have additional comorbidities, cere-
bral autoregulation is thought to be already impaired.28
In addition, a mathematical model of regional cerebral
oxygen uptake also suggested that oxygen uptake in
ischaemic penumbra progressively decreases below an
HL of 10 g/dl.29 Other potential pathophysiological
mechanisms include the modulation of adhesion mole-
cules by hyperdynamic circulation in anaemic
patients30 and the upregulation of inflammatory medi-
ators.1,31 In line, a recent study found a positive
correlation between decreasing baseline HL and
increasing final infarct volume in acute stroke patients.8
The clear and independent association between
anaemia on admission and poor functional outcome
and mortality in acute ischaemic stroke patients carries
the chance for hyperacute interventions. Such an inter-
vention could be red blood cell transfusion (RBCT). In
one retrospective study investigating the optimal man-
agement of HL and RBCT in patients with severe
ischaemic stroke, RBCT was not associated with any
clinical improvement.32 However, the sample size was
small (n¼ 109), and stroke severity was high (median
NIHSS 19). Furthermore, RBCT was performed at the
discretion of the neurologic ICU physician in charge,
based on the general aim to keep HL between 8 and
10 g/dl over the course of the hospitalisation and not
necessarily during the hyperacute phase when the pen-
umbra might still be preserved.
Furthermore, the optimal HL threshold for RBCT is
unclear.33 In general, RBCT is not considered in
patients with HL>10 g/dl. In some ischaemic popula-
tions (i.e. acute coronary syndrome) the threshold for
RBCT is between 8 and 10 g/dl.34 Data on RBCT in
ischaemic patients (i.e. myocardial infarction) with
anaemia remain ambiguous: in some studies, RBCT
reduced mortality35,36 while in others RBCT increased
adverse outcomes after percutaneous coronary inter-
vention37 and in ST-elevation myocardial infarction.38
In anaemic patients with aneurysmal subarachnoid
haemorrhage, RBCTs are suggested to be beneficial
when there was no considerable anaemia beforehand.39
On the other hand, in the setting of perioperative pro-
cedures RBCT was suggested to be associated with
stroke.40 In patients undergoing coronary artery
bypass surgery, the use of solvent/detergent treated
plasma and platelet transfusions seemed to have a
larger impact on the development of stroke than
RBCT.41
Nevertheless, the strong association of anaemia with
poor functional outcome and mortality in acute setting
of IVT-treated stroke patients and the high vulnerabil-
ity of penumbral brain tissue to hypoxia might justify a
randomised controlled trial investigating RBCT in the
hyperacute phase of ischaemic stroke.
In our study, polyglobulia was not associated with
functional outcome, mortality or sICH. In the general
stroke population, a U-shaped relationship between
HL and short-term mortality (up to one month) in
men has been suggested.1 This might indicate that
patients with polyglobulia have a special benefit of
IVT. However, the proportion of patients with poly-
globulia was small (2.7%; n¼ 186) in our study and
results should be interpreted with caution.
Our study has the following strengths: (i) the large
sample size reduced the risk of chance findings and
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allowed adjustment for several confounding variables,
(ii) the low number of missing data on HL (2.9%) and
clinical outcome at three months (3.5%) reduced the
risk of bias and (iii) the prospective and systematic
approach of data assessment was not influenced by
the current research question.
This study has limitations: (i) the TRISP registry is
not monitored and does not provide data from com-
parison group of patients not treated with IVT. Thus,
we were not able to calculate the treatment effect of
IVT stratified to HL categories. (ii) We were neither
able to classify the type of anaemia nor did we have
any information about the underlying cause of anae-
mia, which may affect functional three-month outcome
and mortality, e.g. in the case of cancer-related anae-
mia, anaemia of chronic disease or malnutrition. Due
to insufficient data it was also not possible to fully
incorporate potential confounders such as frailty (i.e.
by a standard measure of comorbidity) which is asso-
ciated with anaemia and poor outcome. However, we
were able to adjust for parameters that are relevant in
anaemia of chronic disease most importantly for renal
function (via estimated glomerular filtration rate) and
for vascular risk factors. Hence chronic disease as a
possible confounder on functional outcome and mor-
tality is partly addressed in the multivariate analyses.
In addition, anaemia might be a manifestation of
chronic, e.g. gastrointestinal, bleeding. In these cases,
IVT treatment is likely to deteriorate outcomes.
However, because IVT is contraindicated in haemor-
rhagic diseases (acute or chronic), the number of these
patients is expected to be very small. (iii) Further, we
have no information on the course of the HL over time
and whether HLs were deliberately altered with RBCT
or iron supplements. (iv) The investigated data were
collected from high volume stroke centres. These
results may not apply to low volume centres.
Conclusions
Anaemia was independently associated with poor clin-
ical outcome and mortality in IVT-treated stroke
patients. The more severe the anaemia, the stronger
the association with poor clinical outcome and mortal-
ity. Therefore, severe anaemia might be a target for
interventions in hyperacute stroke. Anaemia was not
associated with occurrence of sICH and no significant
association between polyglobulia and any outcome was
found.
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